PT526434E - Derivados de benzimidazolona como antagonistas 5-ht1a e 5-ht2. - Google Patents

Derivados de benzimidazolona como antagonistas 5-ht1a e 5-ht2. Download PDF

Info

Publication number
PT526434E
PT526434E PT92830427T PT92830427T PT526434E PT 526434 E PT526434 E PT 526434E PT 92830427 T PT92830427 T PT 92830427T PT 92830427 T PT92830427 T PT 92830427T PT 526434 E PT526434 E PT 526434E
Authority
PT
Portugal
Prior art keywords
formula
compound
dihydro
benzimidazol
compounds
Prior art date
Application number
PT92830427T
Other languages
English (en)
Portuguese (pt)
Inventor
Giuseppe Bietti
Marco Turconi
Ettore Giraldo
Franco Borsoni
Maura Bignotti
Original Assignee
Boehringer Ingelheim Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Italia filed Critical Boehringer Ingelheim Italia
Publication of PT526434E publication Critical patent/PT526434E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT92830427T 1991-07-30 1992-07-30 Derivados de benzimidazolona como antagonistas 5-ht1a e 5-ht2. PT526434E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI912118A IT1251144B (it) 1991-07-30 1991-07-30 Derivati del benzimidazolone

Publications (1)

Publication Number Publication Date
PT526434E true PT526434E (pt) 2000-08-31

Family

ID=11360463

Family Applications (1)

Application Number Title Priority Date Filing Date
PT92830427T PT526434E (pt) 1991-07-30 1992-07-30 Derivados de benzimidazolona como antagonistas 5-ht1a e 5-ht2.

Country Status (31)

Country Link
US (1) US5576318A (cg-RX-API-DMAC7.html)
EP (1) EP0526434B1 (cg-RX-API-DMAC7.html)
JP (1) JP2989667B2 (cg-RX-API-DMAC7.html)
KR (1) KR100263495B1 (cg-RX-API-DMAC7.html)
AT (1) ATE191910T1 (cg-RX-API-DMAC7.html)
AU (1) AU665366B2 (cg-RX-API-DMAC7.html)
CA (1) CA2114542C (cg-RX-API-DMAC7.html)
CZ (1) CZ281511B6 (cg-RX-API-DMAC7.html)
DE (1) DE69230926T2 (cg-RX-API-DMAC7.html)
DK (1) DK0526434T3 (cg-RX-API-DMAC7.html)
EE (1) EE03070B1 (cg-RX-API-DMAC7.html)
ES (1) ES2144412T3 (cg-RX-API-DMAC7.html)
FI (1) FI111460B (cg-RX-API-DMAC7.html)
GR (1) GR3033947T3 (cg-RX-API-DMAC7.html)
HU (2) HUT70195A (cg-RX-API-DMAC7.html)
IE (1) IE922464A1 (cg-RX-API-DMAC7.html)
IL (1) IL102665A (cg-RX-API-DMAC7.html)
IT (1) IT1251144B (cg-RX-API-DMAC7.html)
MX (1) MX9204139A (cg-RX-API-DMAC7.html)
NO (1) NO304070B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ243777A (cg-RX-API-DMAC7.html)
PH (1) PH30998A (cg-RX-API-DMAC7.html)
PL (1) PL171329B1 (cg-RX-API-DMAC7.html)
PT (1) PT526434E (cg-RX-API-DMAC7.html)
RU (1) RU2096411C1 (cg-RX-API-DMAC7.html)
SG (1) SG52407A1 (cg-RX-API-DMAC7.html)
SK (1) SK279292B6 (cg-RX-API-DMAC7.html)
TW (1) TW209862B (cg-RX-API-DMAC7.html)
UA (1) UA42684C2 (cg-RX-API-DMAC7.html)
WO (1) WO1993003016A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA925682B (cg-RX-API-DMAC7.html)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
SE9201138D0 (sv) * 1992-04-09 1992-04-09 Astra Ab Novel phthalimidoalkylpiperazines
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
DK0689536T3 (da) * 1993-03-16 2001-07-30 Pfizer Naphthalenderivater
JP3719612B2 (ja) * 1993-06-14 2005-11-24 塩野義製薬株式会社 ヘテロ環を含有する尿素誘導体
IL114027A (en) * 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
DK0765320T3 (da) * 1994-06-14 2001-11-26 Pfizer Benzimidazolonderivater med central dopaminerg aktivitet
NZ284851A (en) * 1994-08-05 1998-07-28 Pfizer 1-[3-(piperazin-1-yl)-prop-1-yl] benzimidazole derivatives and their use in the treatment of cns disorders
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5889010A (en) * 1995-05-18 1999-03-30 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
WO1997016187A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US6376494B1 (en) 1998-06-15 2002-04-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
WO1999065887A1 (en) * 1998-06-15 1999-12-23 American Home Products Corporation Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6521623B1 (en) 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
JP5062939B2 (ja) * 2000-09-19 2012-10-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
AU2002223528A1 (en) * 2000-09-19 2002-04-02 Boeringer Ingelheim Pharma Gmbh & Co. Kg New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
ES2323451T7 (es) 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
UA76767C2 (uk) * 2001-08-02 2006-09-15 Бідакем С.П.А. Стабільна поліморфна модифікація флібансерину, спосіб її промислового одержання та її застосування для одержання лікарських засобів
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
ES2361994T3 (es) * 2002-05-22 2011-06-27 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevas composiciones farmacéuticas que contienen polimorfo a de flibanserina.
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
OA12923A (en) * 2002-09-17 2006-10-13 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
UA86204C2 (uk) * 2003-09-03 2009-04-10 Пфайзер Инк. Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність
AR045843A1 (es) * 2003-10-03 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
CA2569654C (en) * 2004-06-15 2010-12-21 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
KR100908547B1 (ko) * 2005-02-22 2009-07-20 화이자 인코포레이티드 ５ｈｔ４ 수용체 작용제로서의 옥시인돌 유도체
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006096434A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
BRPI0613430A2 (pt) * 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
US7790726B2 (en) * 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090176698A1 (en) * 2006-02-20 2009-07-09 Boehringer Ingelheim International Gmbh Benzimidazolone Derivatives for the Treatment of Urinary Incontinence
EP2520567A3 (en) * 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
EP1991228A1 (en) * 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Treatment of prevention of valvular heart disease with flibanserin
MX2008013827A (es) * 2006-05-09 2008-11-10 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
WO2008006838A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
JP5514716B2 (ja) 2007-05-11 2014-06-04 コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2238117A1 (en) * 2008-01-24 2010-10-13 NeuroSearch A/S 4-phenyl-piperazin-1-yl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
WO2010146595A2 (en) * 2009-06-16 2010-12-23 Symed Labs Limited Novel polymorphs of flibanserin hydrochloride
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a
US9598387B2 (en) * 2012-10-11 2017-03-21 Southern Research Institute Urea and amide derivatives of aminoalkylpiperazines and use thereof
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076213A1 (zh) * 2015-11-02 2017-05-11 苏州旺山旺水生物医药有限公司 苯并咪唑类化合物、其制备方法及用途
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN106749038A (zh) * 2015-11-25 2017-05-31 山东诚创医药技术开发有限公司 一种氟班色林的制备方法
CN106866546A (zh) * 2015-12-10 2017-06-20 常州爱诺新睿医药技术有限公司 氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN108699007A (zh) 2016-01-31 2018-10-23 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN108349908B (zh) * 2016-02-02 2021-07-20 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑酮化合物及包含该化合物的组合物
CN107235913B (zh) * 2016-03-29 2020-07-10 苏州科伦药物研究有限公司 工业规模高效制造优质氟班色林的方法
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
HU231283B1 (hu) 2018-08-01 2022-09-28 Richter Gedeon Nyrt Eljárás a flibanserin többlépéses folyamatos áramú előállítására
CA3211341A1 (en) * 2021-03-19 2022-09-22 Centre National De La Recherche Scientifique Applications of biased ligands of the serotonin 5-ht7 receptor for the treatment of pain, multiple sclerosis and the control of thermoregulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
YU39992B (en) * 1976-04-02 1985-06-30 Janssen Pharmaceutica Nv Process for obtaining new piperazine and piperidine derivatives
FI791926A7 (fi) * 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
AU2427592A (en) 1993-03-02
JP2989667B2 (ja) 1999-12-13
PH30998A (en) 1997-12-23
NO304070B1 (no) 1998-10-19
TW209862B (cg-RX-API-DMAC7.html) 1993-07-21
SK279292B6 (sk) 1998-09-09
IL102665A (en) 1996-10-31
DE69230926D1 (de) 2000-05-25
ES2144412T3 (es) 2000-06-16
NO940306L (no) 1994-03-14
HU9400255D0 (en) 1994-05-30
FI940420A0 (fi) 1994-01-28
CA2114542C (en) 2004-02-24
IT1251144B (it) 1995-05-04
DK0526434T3 (da) 2000-07-17
CZ281511B6 (cs) 1996-10-16
HK1010725A1 (en) 1999-06-25
ITMI912118A0 (it) 1991-07-30
CA2114542A1 (en) 1993-02-18
HUT70195A (en) 1995-09-28
SG52407A1 (en) 1998-09-28
RU2096411C1 (ru) 1997-11-20
JPH06509575A (ja) 1994-10-27
ATE191910T1 (de) 2000-05-15
NO940306D0 (no) 1994-01-28
ZA925682B (en) 1994-01-31
WO1993003016A1 (en) 1993-02-18
UA42684C2 (uk) 2001-11-15
PL302163A1 (en) 1994-07-11
CZ17094A3 (en) 1994-05-18
DE69230926T2 (de) 2000-10-05
GR3033947T3 (en) 2000-11-30
US5576318A (en) 1996-11-19
IE922464A1 (en) 1993-02-10
MX9204139A (es) 1993-01-01
FI111460B (fi) 2003-07-31
AU665366B2 (en) 1996-01-04
EP0526434A1 (en) 1993-02-03
SK10194A3 (en) 1994-12-07
KR100263495B1 (ko) 2000-11-01
EP0526434B1 (en) 2000-04-19
ITMI912118A1 (it) 1993-01-31
HU211256A9 (en) 1995-11-28
PL171329B1 (pl) 1997-04-30
FI940420A7 (fi) 1994-01-28
EE03070B1 (et) 1998-02-16
NZ243777A (en) 1995-04-27

Similar Documents

Publication Publication Date Title
PT526434E (pt) Derivados de benzimidazolona como antagonistas 5-ht1a e 5-ht2.
JP3880842B2 (ja) １−〔（４−クロロフェニル）フェニルメチル〕ピペラジンの鏡像体およびその製造法
US6284759B1 (en) 2-piperazinoalkylaminobenzo-azole derivatives: dopamine receptor subtype specific ligands
JPS6084282A (ja) １−ヘテロアリ−ル−４−〔（２．５−ピロリジンジオン−１−イル）アルキル〕ピペラジン誘導体
US9598387B2 (en) Urea and amide derivatives of aminoalkylpiperazines and use thereof
JPH0314563A (ja) 新規４―フルオロ安息香酸誘導体
HU201057B (en) Process for producing 6-phenyl-3-(piperazinyl-alkyl)-1h,3h-pyrimidin-2,4-dion derivatives and pharmaceutical compositions containing them
JP2004509873A (ja) セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
GB2174703A (en) Pyridinylpiperazine derivatives
US20040029876A1 (en) Acylamino cyclopropane derivatives
US6593324B2 (en) Dervatives of quinoline as alpha-2 antagonists
JPH0319233B2 (cg-RX-API-DMAC7.html)
DE69431441T2 (de) Trizyklische verbindungen mit affinität für den 5-ht1a rezeptor
AU671361B2 (en) 2-aminopyrazine-5-carboxamide derivatives, their preparation and their application in therapeutics
US20020128274A1 (en) Benzylpiperazinyl-indolinylethanones
HK1010725B (en) Benzimidazolone derivatives as 5-ht1a and 5-ht2 antagonists
US20060122206A1 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
JP2008523027A (ja) ドーパミン−ｄ２受容体に関する親和力およびセロトニン再吸収部位の組み合わせを有するテトラヒドロピリジン−４−イルインドール類